- Global Pharma News & Resources

Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL®

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Aralez Pharmaceuticals Trading DAC, an Irish designated activity company, to become the exclusive distributor in the U.S. of the authorized generic version of Toprol-XL® (Metoprolol Succinate) Extended Release Tablets in 25 mg, 50 mg, 100 mg and 200mg.  For the 12 months ended September 2017, total U.S. sales at Average Wholesale Price (AWP) of Metoprolol Succinate extended release tablets 25 mg, 50 mg, 100 mg and 200 mg were approximately $690 million, according to IMS.  Financial terms were not disclosed.

"Metoprolol Succinate is a widely prescribed medication and will be an important addition to our cardiovascular product offering," said Arthur Bedrosian, chief executive officer of Lannett.  "We expect to launch the product, under the Lannett label, in the near future."

Metoprolol Succinate extended release is a beta-blocker used to treat chest pain (angina), heart failure and high blood pressure.  Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems.